Tamayo Louis Edward sold $21K of LXEO

Tamayo Louis Edward (Chief Financial Officer) sold 4,641 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.49 on 2026-07-01.

Original reporting
SEC EDGAR · Tamayo Louis Edward
Published Jul 1, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXEO
Neutral
medium confidence
Mentioned
$LXEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings). This can marginally affect sentiment but does not provide new operational or financial guidance.

02

Market read

Traders may monitor LXEO for follow-on insider activity, but this filing alone is unlikely to change valuation materially.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context, directional inference is weak.

Relevance 3/10Novelty 5/10Timing: filed 2026-07-01 (after-hours) for an insider sale dated 2026-07-01

Background

The article is a primary-source SEC Form 4 insider transaction for Lexeo Therapeutics, Inc. (LXEO).

Company-level read

Ticker impact

$LXEONeutralMedium confidence
Context

Lexeo Therapeutics CFO Tamayo Louis Edward filed a Form 4 selling 4,641 shares at $4.49 on 2026-07-01, reducing direct holdings to 97,024.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

Form 4 provides a concrete transaction datapoint, but it is not tied to earnings, guidance, financing, litigation, or operational changes in the article.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may view as mildly bearish sentiment.

Key entities

  • Lexeo Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tamayo Louis Edward

    Chief Financial Officer who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXEOMedAI 8/10

Lexeo Therapeutics Stock Jumps 12% On Positive Gene Therapy Data

Lexeo Therapeutics (LXEO) stock rose 12% after positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy. The therapy reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44% in high-dose patients. The company reported a Q3 net loss of $38.3 million, up from $20.3 million last year, with R&D expenses increasing to $34.5 million.

$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.